Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Excler

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
AIDS Research and Human Retroviruses|December 9, 1997
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccinesE Coëffier, J L Excler, M P Kieny, et al.
The Journal of Infectious Diseases|July 1, 1995
A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedulesB Marchou, J L Excler, C Bourderioux, et al.
Journal of Immunological Methods|February 18, 1999
Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipientsM Raux, L Finkielsztejn, D Salmon-Céron, et al.
Sante (Montrouge, France)|January 1, 1996
[Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine]J P Moulia-Pelat, A Spiegel, J L Excler, et al.
Vaccine|May 1, 1994
A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 yearsJ P Moulia-Pelat, A Spiegel, P M Martin, et al.
Vaccine|November 1, 1993
Three-week hepatitis B vaccination provides protective immunityB Marchou, N Picot, P Chavanet, et al.
Sante (Montrouge, France)|January 1, 1995
[Inclusion of hepatitis B vaccination in the Expanded Program of Immunization: feasibility study in the medical region of Kolda (Senegal)]J L Excler, B Yvonnet, Y Gaye, et al.
Developments in Biological Standardization|January 1, 1995
The safety and use of canarypox vectored vaccinesS A Plotkin, M Cadoz, B Meignier, et al.
The Journal of Infectious Diseases|October 1, 1996
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160B Fleury, G Janvier, G Pialoux, et al.
Presse Medicale (Paris, France : 1983)|February 12, 1994
[Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]P Jungers, P Chauveau, A M Couroucé, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
AIDS Research and Human Retroviruses|December 9, 1997
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccinesE Coëffier, J L Excler, M P Kieny, et al.
The Journal of Infectious Diseases|July 1, 1995
A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedulesB Marchou, J L Excler, C Bourderioux, et al.
Journal of Immunological Methods|February 18, 1999
Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipientsM Raux, L Finkielsztejn, D Salmon-Céron, et al.
Sante (Montrouge, France)|January 1, 1996
[Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine]J P Moulia-Pelat, A Spiegel, J L Excler, et al.
Vaccine|May 1, 1994
A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 yearsJ P Moulia-Pelat, A Spiegel, P M Martin, et al.
Vaccine|November 1, 1993
Three-week hepatitis B vaccination provides protective immunityB Marchou, N Picot, P Chavanet, et al.
Sante (Montrouge, France)|January 1, 1995
[Inclusion of hepatitis B vaccination in the Expanded Program of Immunization: feasibility study in the medical region of Kolda (Senegal)]J L Excler, B Yvonnet, Y Gaye, et al.
Developments in Biological Standardization|January 1, 1995
The safety and use of canarypox vectored vaccinesS A Plotkin, M Cadoz, B Meignier, et al.
The Journal of Infectious Diseases|October 1, 1996
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160B Fleury, G Janvier, G Pialoux, et al.
Presse Medicale (Paris, France : 1983)|February 12, 1994
[Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]P Jungers, P Chauveau, A M Couroucé, et al.
Pageof 4